Efficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment

Launched by THE FIRST HOSPITAL OF JILIN UNIVERSITY · Mar 31, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called DS8201 to see how effective and safe it is for treating metastatic breast cancer, which means the cancer has spread to other parts of the body. The researchers want to find out if the results from real-world patients are different from what they see in controlled clinical trials. They aim to gather information that can help improve treatment for patients with this condition.

To be eligible for this study, participants need to be at least 18 years old and have a confirmed diagnosis of breast cancer that has spread. They also need to have received treatment with DS8201 and have complete medical records available for review. The trial is not yet recruiting participants, but once it begins, those who join can expect to have their health monitored closely to assess how well the treatment works and if there are any side effects. This study is important because it will help us understand how DS8201 works in everyday settings, which can lead to better care for patients with metastatic breast cancer.

Gender

ALL

Eligibility criteria

• • Inclusion criteria: (1) age ≥18 years old; (2) breast cancer confirmed by pathological diagnosis; (3) the presence of one or more distant metastatic lesions confirmed by pathology or imaging; (4) patients had received DS8201 treatment; (5) Complete medical records, complete blood routine and liver and kidney function test results during treatment.
• • Exclusion criteria: no history of traceable or missing clinical data.